CHAPTERS
- 0:00 – 0:33
Cold open banter and a Terminator-style joke
Tim Ferriss opens with playful small talk about breakfast and altitude effects. Hamilton Morris responds with a tongue-in-cheek reference before the show transitions into sponsor messages.
- •Tim asks Hamilton what he recalls from breakfast
- •Hamilton answers with minimalist detail about bowl and fork
- •Tim mentions altitude affecting his ability to run before his hands shake
- •Hamilton riffs with a ‘cybernetic organism’ joke tied to the show
- 0:33 – 5:06
Sponsor messages: Inktel customer support + Doris Kearns Goodwin’s leadership book
Tim delivers sponsor segments, first describing how Inktel handled intensive customer service needs during major book launches. He then highlights Doris Kearns Goodwin’s book and the leadership questions it explores through multiple presidential case studies.
- •Tim frames delegation as investing money to improve life quality and save time
- •He describes using Inktel for round-the-clock customer service during launches
- •He promotes “Leadership in Turbulent Times” and the leadership questions it tackles
- •He lists the presidents the book draws upon and emphasizes early development and resilience
- 5:06 – 8:58
Who is Hamilton Morris and what the episode will cover
Tim introduces Hamilton Morris as a writer, documentarian, and scientific researcher studying tryptamines. He previews a wide-ranging conversation about psychedelics, chemistry, global experiences, and unusual characters encountered through Hamilton’s work.
- •Tim introduces Hamilton’s research focus on tryptamines at University of the Sciences in Philadelphia
- •Hamilton’s writing and TV work are highlighted, especially Hamilton’s Pharmacopeia
- •Tim previews chemistry, mind-altering substances, and travel/adventures in the episode
- •Hamilton joins and Tim sets expectations about mispronunciations and complexity
- 8:58 – 16:10
Alexander Shulgin’s life story: from Harvard to backyard research
Hamilton describes Alexander Shulgin as an extraordinary chemist shaped by mid-20th-century science culture and personal experiences. He recounts Shulgin’s early life events, his work at Dow, and how he eventually pursued prolific psychedelic research independently at home.
- •Hamilton recounts Shulgin’s early Harvard experience and leaving to join the Navy
- •A placebo-effect moment with “morphine” in orange juice influences Shulgin’s lifelong interest in drugs and mind
- •Shulgin studies chemistry from older textbooks that included syntheses now considered taboo
- •Shulgin’s Dow career and the latitude he gained after developing a profitable insecticide
- •Shulgin continues research openly from his home, publishing in major journals without university affiliation
- 16:10 – 20:00
Why Shulgin mattered: self-experimentation and ‘experience’ as timeless data
Tim asks what distinguished Shulgin from other chemists, and Hamilton argues it was Shulgin’s perspective on what scientific work remains valuable over time. Hamilton emphasizes Shulgin’s view that subjective experience doesn’t become obsolete the way many assays and fashions in research can.
- •Hamilton notes Shulgin downplayed his own chemistry credentials and emphasized biochemistry interests
- •Hamilton contrasts ‘timeless’ experience with pharmacological assays he considers flawed or obsolete
- •He argues Shulgin prioritized the bottom line of direct human experience
- •Hamilton uses Goethe’s approach to color as a parallel for taking perception seriously
- •Tim probes how subjective reports can be valuable and how generalizable they may be
- 20:00 – 23:33
Risk mitigation in novel compounds and the logic of starting extremely small
Tim asks how Shulgin and similar researchers thought about safety when exploring unknown substances. Hamilton describes a conservative approach: begin with tiny fractions of a plausible dose and escalate gradually, while also noting that even well-known drugs have unresolved toxicity debates.
- •Hamilton frames risk two ways: unknown compounds vs the ongoing uncertainty around widely used drugs
- •He mentions persistent debates about basic toxicity questions for common substances
- •Hamilton describes Shulgin’s published methodology: start around one-tenth of the smallest imaginable dose
- •He gives a hypothetical example of dose escalation in microgram-to-milligram steps
- •He argues gradual escalation can reveal toxicity well before lethal dosing for many poisons
- 23:33 – 27:12
Learning chemistry as a non-chemist: books, videos, and hands-on practice
Tim asks how someone without a chemistry background can become literate enough to engage with Shulgin’s work. Hamilton recommends accessible resources and suggests that practical lab-like activities (done safely and legally) can make chemistry easier to care about and understand.
- •Hamilton says PiHKAL and TiHKAL are accessible to non-chemists due to narrative components
- •He recommends “Organic Chemistry as a Second Language” Part One and Part Two
- •He points to Khan Academy and the broader organic chemistry tutoring ecosystem
- •Hamilton argues practical application is key to learning, not just abstract study
- •He mentions legal/safer hands-on activities like distillation and plant extractions
- 27:12 – 32:03
Hamilton’s early encounters with psychedelics and first appreciation via salvia
Hamilton describes being interested in psychedelics from childhood, but also being wary due to cultural narratives and personal influences. He explains how salvia’s legality and availability led to his first powerful psychedelic experiences and changed how he viewed the limits of description.
- •Hamilton recalls reading about DMT in an educational drug book as a child
- •He recounts being offered LSD around age 12 and asking instead for DMT
- •He describes his father’s fear of LSD influenced by a child psychiatrist’s papers
- •Hamilton explains why he avoided major psychedelic use in high school aside from salvia
- •He says salvia showed him psychedelics were different from common descriptions and hard to convey in words
- 32:03 – 46:03
Science vs shamanism, why dose matters, and the problems with plant variability
Tim asks why psychedelics are culturally misunderstood and explores tensions between scientific and shamanic framings. Hamilton critiques dogma, emphasizes experimentation and tailoring experiences, and repeatedly returns to dosing accuracy as central—especially versus variable plant preparations.
- •Hamilton says psychedelics are marginalized partly because society lacks frameworks to ‘place’ the experiences
- •He says he isn’t spiritual and questions what ‘spiritual’ means, but values emergent gratitude and love
- •Hamilton critiques the idea that plants are the ‘be all, end all,’ preferring room for derivatives and exploration
- •He compares DMT vs DPT in terms of personal vs universal-feeling experiences
- •Hamilton argues dose is often ignored and that plant brews, LSD blotters, and mushrooms have major potency uncertainty
- 46:03 – 50:02
Why Hamilton made the show: clandestine chemistry, media narratives, and drug value
Hamilton explains his motivations for creating Hamilton’s Pharmacopeia, emphasizing what journalism avoids or distorts. He focuses on correcting misconceptions about clandestine chemists and arguing that drugs are foundational to consciousness, medicine, and pharmacology—not a niche topic.
- •Hamilton describes shifting media narratives about which drugs are ‘allowed’ to be framed as good or bad
- •He says clandestine drug synthesis is widely misrepresented and demonized
- •He contrasts praise for academic research with condemnation of underground providers who risk freedom
- •He says a key goal was to show drugs as scientific tools and a central human concern
- •He wants viewers to take the subject seriously beyond ‘just drugs’ stereotypes
- 50:02 – 1:09:52
Episode recommendations and on-the-ground realities: 5-MeO-DMT, safety, and film choices
Tim asks which episodes to start with for different audiences, and Hamilton highlights chemistry-heavy episodes and shamanism-oriented ones. The conversation turns to 5-MeO-DMT risks, criticism of filming choices near water, and stories illustrating why supervision and setting matter.
- •Hamilton recommends “A Clandestine Chemist’s Tale,” describing a filmed MDMA synthesis from root bark oil to recrystallized MDMA HCl
- •He mentions filming synthesis work related to Quaalude and gaboxadol and touching on LSD chemistry
- •Hamilton notes the mushroom episode was his most popular and that viewers gravitate to shamanism-focused episodes
- •He discusses unsafe ‘cocky’ attitudes toward 5-MeO-DMT and stresses seriousness without prescribing moral rules
- •Hamilton recounts a death associated with 5-MeO-DMT use (asphyxiation on vomit) and explains criticism about sessions filmed near water
- 1:09:52 – 1:16:56
Ayahuasca, dogma, tragedy, and the value of confronting mystery without explanations
Hamilton explains why he hasn’t featured ayahuasca in the way people expect and criticizes elitism around ‘only valid in the Amazon’ narratives. He discusses the Kyle Nolan case as an example of misplaced priorities, then expands into why interpretive frameworks can be comforting—and why facing the mystery alone can be powerful.
- •Hamilton says he tried to do a story connected to the death of Kyle Nolan and concerns about safety and accountability
- •He criticizes the idea that ayahuasca only ‘counts’ if done in the Amazon and calls it elitist
- •He describes how tourism demand can produce non-traditional experiences marketed as traditional
- •He recounts reports of a retreat shaman claiming extreme stories and people hesitating to question it
- •Hamilton argues interpretive frameworks (religion, shamanic cosmologies) can be appealing, but confronting uncertainty without explanation can be uniquely powerful
- 1:16:56 – 1:21:45
Pharmahuasca experiences: overwhelming ‘deconstruction’ vs practical insights about addiction
Hamilton shares a high-intensity pharmahuasca experience and how hard it is to integrate experiences of that magnitude. He contrasts that with lower-dose sessions that produced actionable insights, including a moment reframing his relationship to nicotine and compulsive ‘wanting more.’
- •Hamilton clarifies he means synthetic DMT with moclobemide when discussing pharmahuasca
- •He describes profound disorientation: loss of time sense and identity, life perceived as pages in a book
- •He says he’s reluctant to force explanatory frameworks onto experiences he can’t comfortably interpret
- •He says lower doses can be more practically beneficial than the most extreme states
- •He recounts realizing the ‘want more’ thought pattern underlying addiction and rejecting nicotine gum in that moment
- 1:21:45 – 1:25:31
Wade Davis, the zombie hypothesis, and field-exploration storytelling
Tim asks Hamilton to describe Wade Davis, and Hamilton summarizes Davis’s controversial work linking Haitian zombification to pharmacology. Hamilton also explains why Davis draws suspicion—both for bold claims and for being a compelling storyteller—while acknowledging his prolific output and fieldwork influence.
- •Hamilton identifies Wade Davis as a student of Richard Evans Schultes and an ethnobotanist
- •He summarizes “The Serpent and the Rainbow” and the pharmacological theory involving scopolamine and pufferfish toxin (TTX)
- •Hamilton notes Davis faced intense criticism and accusations related to evidence handling
- •He mentions Davis’s claimed discoveries (including a psilocybin-containing lichen) that others haven’t replicated
- •Tim asks whether Hamilton tries to emulate that field-exploration and cultural investigation approach
- 1:25:31 – 1:31:25
Ibogaine: anti-addiction interest, cardiotoxicity concerns, and possible Parkinson’s relevance
Hamilton introduces ibogaine as a complex alkaloid from Tabernanthe iboga and explains why it drew attention for opioid addiction interruption. He also discusses broader anti-compulsive effects, safety concerns tied to cardiotoxicity, and research threads connecting ibogaine to GDNF and Parkinson’s disease questions.
- •Hamilton describes ibogaine’s plant source and difficulty of synthesis, noting commercial supply is plant-extracted
- •He recounts Howard Lotsof’s experience and ibogaine’s association with reducing heroin desire
- •He says ibogaine appears to affect more than opioid addiction, including alcoholism and methamphetamine addiction
- •Hamilton raises safer alternative dosing strategies vs high ‘flood doses’ due to cardiotoxicity and deaths
- •He discusses ibogaine’s relationship to GDNF and why that could matter for Parkinson’s, including reports of low daily dosing by some users
- 1:31:25 – 1:37:26
Synthesis vs natural sourcing: sustainability, conservation, and toad-venom uncertainty
Tim asks whether synthesis is a scalable, sustainable alternative to harvesting plants or animals for psychoactive compounds. Hamilton argues synthesis often improves sustainability and dosing certainty, while also emphasizing conservation of plants and unanswered scientific questions about 5-MeO-DMT toads.
- •Hamilton says synthesis is typically more sustainable and highlights lost discovery potential when plants are treated only as crops
- •He argues genetic reserves matter for studying novel compounds and for selective breeding possibilities
- •He points to unanswered basic science questions about 5-MeO-DMT toads (venom regeneration, sensitivity to their own venom)
- •He notes 5-MeO-DMT can be synthesized (mentioning melatonin as a starting point) rather than ‘harassing a toad’
- •Hamilton stresses synthetic purity and quantified dosing vs variable, rarely quantified venom mixtures
- 1:37:26 – 1:41:34
Defining ‘alkaloid’ and shifting to nootropics and cognitive enhancers
Tim asks for a plain definition of ‘alkaloid,’ and Hamilton explains it in chemical terms and why the category matters for extraction. The conversation then pivots to cognitive enhancers, including the problem of self-assessment and how ‘feeling smarter’ can diverge from measurable improvement.
- •Hamilton defines an alkaloid (strictly) as a plant-isolated compound containing a basic nitrogen atom
- •He notes THC and salvinorin A don’t meet the strict alkaloid definition due to lacking nitrogen
- •Hamilton connects the term to classical acid-base extraction behavior
- •He questions how to validate true cognitive enhancement and raises the Dunning–Kruger self-assessment problem
- •He asks what ‘intelligence’ means operationally (memory, creativity, focus, problem-solving, etc.)
- 1:41:34 – 1:48:13
Hamilton’s personal ‘smart drug’ shortlist and how psychedelics might change problem-solving
Hamilton discusses what he’s tried, what he still uses, and why the stimulating classics often dominate. He also explains why compounds like 2C-D interest him conceptually (synesthesia and memory) and why psychedelics may help by changing perspective rather than increasing raw intelligence.
- •Hamilton says nicotine gum is the nootropic he still uses most, especially for reading focus
- •He names other compounds he’s tried and characterizes them as only ‘okay’ for him
- •He discusses 2C-D and the hypothesis that synesthesia-like cross-linking might aid recall
- •He notes psychedelics may help problem-solving by providing different perspectives, referencing James Fadiman’s interest
- •Hamilton lists caffeine and occasional low-dose Ritalin, while acknowledging addiction risks and defining his ‘low dose’ as 10 mg
- 1:48:13 – 1:55:17
Wrap-up: where to find Hamilton, funding basic science, and final book recommendations
Tim and Hamilton close with where to follow Hamilton’s work and how to watch his show. Hamilton makes an explicit request for support for non-clinical basic research, describes a current autoradiography project, and reiterates the value of PiHKAL as a foundational read.
- •Hamilton lists his Twitter/Instagram handle and mentions a forthcoming website
- •He explains where Hamilton’s Pharmacopeia can be purchased or watched (including being free on Hulu per his description)
- •Hamilton asks psychedelic philanthropists to support basic chemistry/pharmacology research without immediate clinical goals
- •He describes a current autoradiography effort with radiolabeled drug distribution in rodent brain tied to sound distortion questions
- •Hamilton strongly recommends PiHKAL as a moving and informative entry point, suggesting TiHKAL as a follow-on
- 1:55:17 – 2:01:18
Post-episode notes: newsletter plug and additional sponsor messages
Tim adds a postscript promoting his ‘5-Bullet Friday’ email and where to find show notes and links. The episode ends with additional sponsor reads repeated from earlier segments.
- •Tim describes the ‘5-Bullet Friday’ email as a short weekly roundup of interesting finds
- •He directs listeners to a website signup to receive the newsletter
- •He reiterates that show notes will include links to resources mentioned (including Shulgin methodology and the Fadiman episode)
- •The episode closes with repeated sponsor content for the leadership book and Inktel
